Dr. Reddy's Laboratories (DRREDDY) Fundamentals 2026 — P/E 23.0x, Revenue Analysis | SniperIQ
Dr. Reddy's Laboratories (DRREDDY) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹98,488 Crore, trading at ₹1183.00 on the BSE. This SniperIQ fundamentals page covers Dr. Reddy's Laboratories's valuation (P/E 23.0x, P/B 2.6x), profitability (net margin 12.8%), revenue (₹33,593 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dr. Reddy's Laboratories's market cap?
Dr. Reddy's Laboratories (DRREDDY) has a market capitalization of approximately ₹98,488 Crore, trading at ₹1183.00 on the BSE. Market cap moves with the live share price.
What is Dr. Reddy's Laboratories's P/E ratio?
Dr. Reddy's Laboratories's trailing twelve-month P/E ratio is 23.0x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories runs a net profit margin of 12.8%, a gross margin of 52.8%, and an operating margin of 14.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dr. Reddy's Laboratories generate?
Dr. Reddy's Laboratories reported revenue of ₹33,593 Crore for fiscal year 2026, with net income of ₹4,285 Crore and earnings per share (EPS) of 51.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dr. Reddy's Laboratories pay a dividend?
Dr. Reddy's Laboratories offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dr. Reddy's Laboratories financially healthy?
Dr. Reddy's Laboratories carries a debt-to-equity ratio of 0.24x and a current ratio of 1.80x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dr. Reddy's Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dr. Reddy's Laboratories (DRREDDY) the key facts are: market cap ₹98,488 Crore, P/E 23.0x, revenue ₹33,593 Crore, 52-week range 1025.9-1377.95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dr. Reddy's Laboratories's full fundamentals live
Get Dr. Reddy's Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.